SIMULATIONS PLUS INC (SLP)
Health Care · Pharmaceutical software and consulting services · NASDAQ
Simulations Plus provides advanced modeling and simulation software and services to accelerate drug discovery and clinical development for the life sciences industry.
What SIMULATIONS PLUS INC does
Simulations Plus develops and licenses specialized software for modeling and simulation in pharmaceutical research and development, clinical trial design, and regulatory support. The company provides both software products and professional services to pharmaceutical, biotech, and healthcare companies. Its platform helps customers predict drug behavior, optimize dosing, and accelerate the drug development process.
Themes: Drug development software and services, Regulatory compliance / FDA submissions, Pharmaceutical simulation and modeling, Biotech consulting and expert services, Clinical development support
Fundamentals
- Price$18.40 as of 2026-08-21 close
- Market cap$372M as of 2026-08-21
- 1-year return+33.6% 2025-08-21 close $13.77 → 2026-08-21 close $18.40
- P/E45.71 as of 2026-08-24
- Net margin+9.9% as of 2026-08-24
- Gross margin+63.4% as of 2026-08-24
- ROE+6.2% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+2.1% as of 2026-08-24
- Revenue CAGR (3y)+13.7% SEC XBRL
- Beta1.32 as of 2026-08-24
- Last reported earnings2026-07-09 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.6%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How SLP compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 25% 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which SLP reported a dividend payment is FY2024, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2024 ratio would not describe SLP today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2024) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How SIMULATIONS PLUS INC looks technically
SIMULATIONS PLUS INC (SLP) is trading 12.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 37 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day high, its first since 2026-01-28, pushing above its recent trading range. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 33% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 12.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +12.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $18.17 | $18.17 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.30 | $16.30 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 52 calendar days ago — the swings before that are what the structure reading is measured on | 52 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 37 trading days ago — a "golden cross", a bullish long-term signal | 37 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 36, with buyers in control | 35.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 64, neither overbought (above 70) nor oversold (below 30) | 64.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($18.29 to $18.41) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. Read that with care: its whole 14-day range is only about 0.7% of the price, so being at one end of it is a smaller move than it sounds — a company pinned near an agreed takeover price does this. | 92.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 36 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $21.01 | $21.01 |
|---|---|---|
| From the 52-week high | it is 12.4% below its 52-week high (its highest price of the past year) | -12.4% |
| Above the 52-week low | it is 65.9% above its 52-week low (its lowest price of the past year) | +65.9% |
| Below the 52-week high | it is 12.4% below its highest point of the past year | 12.4% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-01-28, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-01-28, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $90.92 (set on 2021-02-08) | $90.92 |
| Given back of the 52-week move | over the past year its closes ranged ($11.36 to $20.84), and it has recovered well over two thirds of its fall from last year’s high — 74% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.22 to $17.52. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 74.3% |
| From the all-time high | it is 79.8% below its all-time high | -79.8% |
| Nearest price level | it is trading 0.7% above a support level at $18.27 — a price it turned at three times since 2026-07-21, most recently on 2026-07-31. Since 2024-08-21 it has 11 such levels below the current price and 8 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.7% |
| All-time low | its lowest closing price on record is $0.7125 (set on 2005-10-31) | $0.7125 |
| Above the all-time low | it is 2482.4% above its all-time low | +2,482% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.0905 between its high and its low — about 0.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.0905 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.26 and $18.40 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.26 – $18.33 – $18.40 |
| Typical daily range (% of price) | its price moves about 0.5% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.5% |
| Stretch from the 200-day average | it is trading 23.2 daily ranges above its 200-day average price (12.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.5% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 23.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 33% of its 30-day average | 0.33× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 11.5% above the previous close 46 sessions ago and has not traded back through the level it left behind at 16.32 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +11.5% |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +0.22% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 1.4 percentage points (the stock gained 0.9% while the market gained 2.3%) | -1.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 18.7 percentage points (the stock gained 21.8% while the market gained 3.1%) | +18.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 46.7 percentage points (the stock gained 57.8% while the market gained 11.1%) | +46.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 13.1 percentage points (the stock gained 33.6% while the market gained 20.5%) | +13.1% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 9.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +3.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 14% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $16.19 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +13.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-09 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $18.28 — a volume-weighted average of daily closes over 32 sessions, not a true tick-by-tick VWAP. | +0.7% |
Price levels it has turned at before
SLP last closed at $18.40 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 8 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $18.27 | Support | 0.7% below the last close | turned there three times · 2026-07-21 to 2026-07-31 |
| $18.62 | Resistance | 1.2% above the last close | turned there twice · 2026-06-16 to 2026-06-30 |
| $18.95 | Resistance | 3.0% above the last close | turned there twice · 2025-07-01 to 2025-10-29 |
| $17.75 | Support | 3.5% below the last close | turned there twice · 2025-12-18 to 2026-06-01 |
| $16.72 | Support | 9.1% below the last close | turned there four times · 2025-06-25 to 2025-12-01 |
| $20.89 | Resistance | 13.5% above the last close | turned there twice · 2025-12-04 to 2026-01-23 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Broke out to a new 20-day high · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) · beating the market · Least volatile (2% or less typical daily range) | Learn: moving average · golden cross · adx · rsi · breakout · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$17.25 range $16.00 – $18.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for SLP
- Consensus EPS estimate$0.1325 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Unprofitable on a net income basis with -77.96% net margin; subject to revenue and margin pressure from competitive and evolving pharma software landscape","Highly dependent on software revenue stability and ability to retain customers in a competitive market with larger established players","Dependent on successful commercialization and adoption of modeling/simulation tools which requires significant customer investment in training and integration"]
What changed in the latest 10-Q
AI-assisted comparison of SLP's 10-Q filed 2026-07-09 against the prior one filed 2026-04-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Added bullet points in Forward-Looking Statements section listing specific forward-looking statement topics including: proposed Merger, stockholder approval, regulatory approvals, financing arrangements, business strategy pending Merger completion, investments in cloud-enabled platforms and AI-enabled capabilities, and other merger-related items (filed 2026-07-09)
- Added reference to 'Part II, Item 1A "Risk Factors" in this Quarterly Report on Form 10-Q' in the risk factors disclosure (filed 2026-07-09)
- Added new Results of Operations section comparing three months ended May 31, 2026 vs May 31, 2025 with complete financial table and narrative analysis (filed 2026-07-09)
- Removed:
- Removed reference to 'MIDD' descriptor before 'software and services' in the Executive Overview (filed 2026-07-09 removes language present in filed 2026-04-10)
- Removed the complete Results of Operations section comparing three months ended February 28, 2026 vs February 28, 2025, including the detailed financial table and narrative analysis (filed 2026-07-09 removes this section present in filed 2026-04-10)
- Reworded:
- Changed 'This quarterly report and the documents incorporated in this Quarterly Report by reference' to 'This document and the documents incorporated in this document by reference' in Forward-Looking Statements opening (filed 2026-04-10 used more specific phrasing; filed 2026-07-09 uses generic phrasing)
- Changed 'macro-economic' to 'macroeconomic' in Executive Overview (filed 2026-07-09)
- Changed reference from 'this document' and 'this Quarterly Report' to be consistent with earlier filing language (filed 2026-04-10 to filed 2026-07-09 shows reversion to generic 'document' terminology in some places)
- Notes:
- The two filings compare different quarterly periods: the newer filing (filed 2026-07-09) covers the period ended May 31, 2026, while the older filing (filed 2026-04-10) covers the period ended February 28, 2026. This is a natural seasonal rotation in quarterly reporting rather than an amendment.
- Forward-looking statements section in newer filing includes substantially expanded bullet-point list of merger-related topics, suggesting significant corporate transaction activity between the two filing dates.
Risk Factors
- Added:
- Newer filing (2026-07-09) includes nine months ended May 31, 2026 financial data; older filing (2026-04-10) reports only six months ended February 28, 2026
- Newer filing adds three months ended May 31, 2026 comparative statements; older filing reports three months ended February 28, 2026
- Newer filing balance sheet dated May 31, 2026; older filing balance sheet dated February 28, 2026
- Newer filing shows cash and cash equivalents of $35,324 thousand at May 31, 2026; older filing shows $25,727 thousand at February 28, 2026
- Newer filing reports net income of $8,786 thousand for nine months ended May 31, 2026; older filing reports $5,211 thousand for six months ended February 28, 2026
- Newer filing includes impairments line item of $0 for three and nine months ended May 31, 2026
- Newer filing reports earnings per share (basic) of $0.44 for nine months ended May 31, 2026; older filing reports $0.26 for six months ended February 28, 2026
- Newer filing stockholders' equity of $139,035 thousand at May 31, 2026; older filing shows $133,771 thousand at February 28, 2026
- Removed:
- Older filing includes impairments of $77,221 thousand in comparison period (three and six months ended May 31, 2025); newer filing comparison shows $0 impairment for same periods
- Older filing six months ended February 28, 2026 data removed in newer filing; replaced by nine months ended May 31, 2026
- Older filing three months ended February 28, 2026 data replaced by three months ended May 31, 2026 in newer filing
- Reworded:
- Statement title change: 'CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME' (older) to 'CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)' (newer)
- Consolidated statements of cash flows period changed from 'Six Months Ended' (older) to 'Nine Months Ended' (newer)
- Operating expenses line item description: 'Impairments — 77,221' appears in older filing May 31, 2025 comparative column but is absent from newer filing equivalent comparison
- Notes:
- The newer filing represents a subsequent quarterly period (May 31, 2026) compared to the older filing (February 28, 2026), resulting in different reporting periods rather than restatements of the same period
- Financial data differences reflect the progression of time and operational results for the interim periods, not amendments to previously reported information
- The older filing May 31, 2025 comparative column in the newer filing shows $77,221 thousand in impairments, whereas the newer filing May 31, 2026 comparative column shows $0 impairments for the same prior year period
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($18280) — 1 selling insider
- Last 90 days0 buys · 7 sells ($542719) — 3 selling insiders
- Last 180 days0 buys · 11 sells ($814549) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about SLP's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding SLP as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 2,014,477
- Reported value $23,811,122
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
SLP had 2,844,266 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
SLP had 14.1% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.24 days to cover at the same settlement.
- Reported short interest (shares) 2,844,266
- Short interest (% of shares outstanding) 14.1%
- Prior settlement (shares) 1,780,772
- Reported change 59.72%
- Days to cover (reported) 5.24
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Certara (drug development software and CRO services)
- Pharsight (part of Certara)
- PharMetrics (pharmacokinetic research data)
- Genedata (drug discovery informatics)
- Schrödinger (computational chemistry and drug discovery)
- Pharmaceutical companies
- Biotechnology companies
- Contract research organizations (CROs)
- Regulatory agencies
- Unprofitable operations with -77.96% net margin, though recent quarters show a return to profitability; accumulated deficit of $25.6M as of May 2026
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare SLP vs…
SLP shows up in…
Frequently asked questions
What does SIMULATIONS PLUS INC (SLP) do?
Simulations Plus develops and licenses specialized software for modeling and simulation in pharmaceutical research and development, clinical trial design, and regulatory support. The company provides both software products and professional services to pharmaceutical, biotech, and healthcare companies. Its platform helps customers predict drug behavior, optimize dosing, and accelerate the drug development process.
What sector is SIMULATIONS PLUS INC (SLP) in?
SIMULATIONS PLUS INC (SLP) is classified in the Health Care sector. Its industry is Pharmaceutical software and consulting services. It trades on NASDAQ.
Does SLP pay a dividend?
Yes — SIMULATIONS PLUS INC (SLP) pays a dividend, with an indicated yield of about 0.61% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are SIMULATIONS PLUS INC's (SLP) competitors?
Notable peers of SIMULATIONS PLUS INC (SLP) include Certara (drug development software and CRO services), Pharsight (part of Certara), PharMetrics (pharmacokinetic research data), Genedata (drug discovery informatics) and Schrödinger (computational chemistry and drug discovery). This peer set is informational only — not financial advice.
Is SIMULATIONS PLUS INC (SLP) overbought or oversold right now?
SIMULATIONS PLUS INC (SLP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 64, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on SLP come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.